Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics (NRIX) filed a Form 3 reporting the initial beneficial ownership status of director Roger Dansey following an event dated 11/06/2025. The filing states that no securities are beneficially owned. The form was filed by one reporting person and signed by an attorney-in-fact under a Power of Attorney.
Nurix Therapeutics appointed Roger Dansey, M.D. to its Board of Directors and to the Board’s Clinical and Commercialization Committee, effective immediately. He will serve as a Class III director with a term expiring at the company’s 2026 annual meeting of stockholders.
Compensation follows the non-employee director program: a pro rata portion of the $50,000 annual board retainer and a pro rata portion of the $7,500 committee retainer for the remainder of the fiscal year ending November 30, 2025. On November 6, 2025, the Board granted Dr. Dansey an initial stock option for 50,000 shares at the Grant Date closing price, vesting monthly over three years, subject to continued service. He will also be eligible for the customary annual 25,000-share option at each annual meeting, vesting by the next annual meeting or one year, whichever is earlier. Both the Initial Award and each Annual Award accelerate in full upon a Corporate Transaction.
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Financial Officer. On 11/03/2025, the CFO sold 6,284 shares of common stock in an open-market transaction pursuant to a previously adopted Rule 10b5-1 trading plan.
The sale had a weighted average price of $12.5607, with individual sales ranging from $12.32 to $13.14. Following the transaction, the officer beneficially owns 37,592 shares directly.
Nurix Therapeutics (NRIX) Form 4: Chief Financial Officer Hans van Houte reported RSU-to-share conversions and a tax-related sale on 10/30/2025. Multiple RSU tranches converted to common stock at no cost: 2,886, 2,000, 3,750, and 2,858 shares. To cover withholding taxes tied to these vestings, he executed a mandated “sell-to-cover” of 3,130 shares at a weighted average price of $12.7967.
Following these transactions, he beneficially owned 43,876 shares of common stock directly. The RSUs vest quarterly under existing schedules, and each RSU represents the right to receive one share upon vesting.
Nurix Therapeutics (NRIX) reported insider activity by its Chief Legal Officer, Christine Ring. On 10/30/2025, multiple restricted stock unit (RSU) vestings converted into common stock via code “M” totaling 10,532 shares (1,924; 2,000; 3,750; 2,858), each at $0 per the RSU terms. A subsequent sale of 3,644 shares at a weighted average price of $12.7967 was executed to cover tax withholding obligations under a required “sell-to-cover” arrangement.
Following these transactions, the reporting person held 50,897 shares directly. Each RSU represents a right to receive one share upon vesting, with tranches vesting quarterly pursuant to previously granted awards.
Nurix Therapeutics (NRIX) reported an insider transaction by its Chief Scientific Officer on Form 4. On 10/30/2025, multiple restricted stock unit (RSU) vestings were settled into common stock, including 3,207; 2,000; 3,750; and 2,858 shares at $0 per share. The insider also sold 4,087 shares at a weighted average price of $12.7967 to satisfy tax withholding via a mandated “sell to cover.” Following these transactions, the insider directly owned 76,751 shares.
Nurix Therapeutics (NRIX) filed a Form 4 reporting an equity grant to its Chief Scientific Officer. On 10/14/2025, the reporting person received 20,000 restricted stock units (RSUs), each representing a right to receive one share of Nurix common stock.
The RSUs were reported at a price of $0 for the derivative security and are held as direct ownership. The award will vest on the second anniversary of the date of grant, contingent on continuous service through that date, after which shares will be delivered. RSUs do not have an expiration date; they either vest or are canceled prior to vesting.
Nurix Therapeutics (NRIX) launched a primary offering of 24,485,799 shares of common stock at a public offering price of $10.21 per share. The transaction implies a gross offering amount of $250,000,007.79, underwriting discounts and commissions of $15,000,000.47, and proceeds to Nurix before expenses of $235,000,007.32. The company estimates net proceeds of approximately $234.3 million after offering expenses.
Nurix plans to use the cash to fund clinical development, including bexobrutideg in CLL and potential autoimmune indications, expand R&D, and for working capital and general corporate purposes; it may also consider in-licensing or acquisitions. Based on its plans, management states this funding, combined with existing cash and investments, supports operations into 2028.
J.P. Morgan, Jefferies, and Stifel are joint bookrunners; delivery is expected on or about October 23, 2025. Shares outstanding will be 101,358,485 immediately after the offering. Shares outstanding were 76,872,686 as of August 31, 2025. The filing notes immediate dilution of $4.23 per share at the $10.21 offering price. Directors and officers, and the company, agreed to a 60‑day lock-up, subject to customary exceptions.
Nurix Therapeutics announced an underwritten public offering, agreeing to issue and sell 24,485,799 shares of common stock at an offering price of $10.21 per share. The company estimates net proceeds of approximately $234.3 million after underwriting discounts, commissions, and expenses.
Nurix plans to use the proceeds primarily to fund clinical development of its drug candidates, including the clinical development of bexobrutideg in chronic lymphocytic leukemia and for potential autoimmune indications, as well as broader R&D, working capital, and general corporate purposes. The offering is being conducted under the company’s shelf registration statement on Form S-3 and a related prospectus supplement, with J.P. Morgan, Jefferies, and Stifel acting as representatives of the underwriters.
Nurix Therapeutics (NRIX) announced initiation of the DAYBreak Phase 2 trial of bexobrutideg (NX-5948), a pivotal single-arm study in relapsed/refractory CLL/SLL. The study will enroll approximately 100 patients whose disease progressed after a covalent BTK inhibitor, a non-covalent BTK inhibitor, and a BCL-2 inhibitor. The primary endpoint is objective response rate per iwCLL criteria assessed by an independent review committee, and the first site was activated in October 2025.
The company selected a 600 mg once-daily dose based on Phase 1b data and alignment with U.S., U.K., and EU regulators, and plans a global randomized Phase 3 confirmatory trial in the first half of 2026 with ~400 patients comparing bexobrutideg to investigator’s choice regimens. Nurix also reported Phase 1a data for NX-1607 in solid tumors, with a disease control rate of 49.3% among 71 evaluable patients as of July 26, 2025, including a confirmed partial response in MSS colorectal cancer and a tolerable safety profile.